Related Experiment Video
Updated: Feb 20, 2026

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.9K
Metaheuristic-driven dual-layer model for classifying Alzheimer's disease stages
Luka Anicin1, Svetlana Andjelic1, Marija Markovic Blagojevic1
1Faculty of Informatics and Computing, Singidunum University, Belgrade, Serbia.
Frontiers in Computational Neuroscience
|February 19, 2026
Summary
This study introduces a machine learning framework for Alzheimer's disease (AD) staging using MRI scans. The advanced model achieved 89.55% accuracy, offering improved diagnosis and patient management.
Area of Science:
- Neuroimaging and Artificial Intelligence
- Computational Neuroscience
- Medical Diagnostics
Background:
- Accurate Alzheimer's disease (AD) staging is vital for patient care and treatment.
- Distinguishing between AD progression stages using neuroimaging is challenging.
Purpose of the Study:
- To develop an advanced machine learning framework for multi-stage Alzheimer's disease classification.
- To enhance the accuracy and interpretability of AD staging using MRI data.
Main Methods:
- A two-tier machine learning architecture combining Convolutional Neural Networks (CNNs) for feature extraction and ensemble models (XGBoost, LightGBM) for classification.
- Application of metaheuristic optimization strategies to refine model performance.
- Evaluation on a public Alzheimer's disease dataset.
Main Results:
- The proposed framework achieved a maximum classification accuracy of 89.55% for multi-stage AD classification.
- Demonstrated robust predictive performance and strong generalization capabilities across different experimental configurations.
- Explainable AI (XAI) techniques provided insights into neuroimaging biomarkers related to AD progression.
Conclusions:
- The developed framework effectively classifies Alzheimer's disease progression stages using MRI data.
- Incorporation of XAI enhances model interpretability and clinical relevance.
- This approach offers a promising direction for data-driven Alzheimer's diagnosis and staging research.
Related Concept Videos
Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Alzheimer's Disease: Treatment
1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
Dementia
591
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
591

